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Introduction
Apoptosis, or programmed cell death, is now recognized as the physiological mechanism by which large numbers of unwanted cells are deleted from the body [ 13. T h e scant evidence of dying cells in situ is explained by the existence of mechanisms for the specific and rapid removal of apoptotic cells by phagocytes. Phagocytosis is one of the earliest markers for the commitment of a cell to apoptosis and occurs before DNA frag- 
Class A scavenger receptors
Scavenger receptors (SR) are a diverse family of proteins that share the common property of binding modified lipoproteins [8] and are, therefore, important in the development of vascular disease [9] . However, they have recently been shown to display high-affinity binding for a wide range of ligands and this property, combined with their patterns of expression, has suggested that they contribute to a number of biological processes [7, 10] . The structures and specific ligand-binding properties indicates there are at least five classes of SR [ll] . Class A SR, which will be the focus of this article, is currently composed of three members; SR-A type I and I1 and the receptor known as MARCO. MARCO has a very restricted distribution; it is expressed mainly in the spleen and will not be discussed further [12] . SR-A types I and I1 are trimeric membrane glycoproteins that are alternatively spliced transcripts from a single gene [13] . Type I and I1 are multi-domained and differ only by the presence of the scavenger receptor cysteinerich domain in the type I molecule. The remainder of the extracellular part of each receptor is identical and is composed of a short spacer domain, and a-helical coiled-coil domain necessary for trimerization and a collagen-like domain that includes the binding site for acetylated low density lipoprotein ( Figure 1 ) [13] . Studies of the endocytosis of modified lipoprotein by SR-A have found that a broad range of diverse molecules are ligands that are able to compete for the lipoprotein binding site of the receptor [10, 11] . Ligands include specific modifications of certain proteins, polyribonucleotides, polysaccharides, cell wall components of prokaryotes and nonphysiological compounds derived from the environment ( Table 1 ). The common feature of these molecules is that they are all polyanionic, but this feature alone is not sufficient to identify a ligand and we currently have a poor understanding of the structural requirements that define a ligand (for discussion of this point see [ 141) . Importantly, the combination of diverse ligand binding with their restriction in expression to M+, have suggested that SR-A I and I1 The generation of a monoclonal antibody (mAb) against murine SR-A has enabled more detailed investigations of the activities and distributions of the receptor. Indeed this mAb (clone 2F8) was isolated through its ability to inhibit a divalent cation-independent component of M+ adhesion [15] . This reagent has been used to determine the tissue expression of SR-A and the antigen was found to be almost exclusively on M+ (with the exception of the sinusoidal hepatic endothelium) [18] . Tissue M+ populations that express SR-A I and I1 include those of the marginal zone of the spleen, alveolar macrophages, heart and gut. We also observed prominent staining with the 2F8 mAb of tissue M+ in the cortical and medullary regions of the thymus. The expression of the receptor in the thymus, in which there is extensive apoptosis in the immature thymocyte populations, and the Volume 26 knowledge that these dying cells are engulfed by thymic M 4 [19] , suggested SR-A as a candidate receptor for the recognition and phagocytosis of apoptotic thymocytes. Although there is compelling evidence for other SR, such as CD36, in the ingestion of apoptotic cells [20] the receptors that are responsible for clearance in the thymus have not been defined.
SR-A and the phagocytosis of apoptotic cells
In order to explore the involvement of SR-A in the removal of apoptotic thymocytes we isolated thymic M4 and developed a phagocytosis assay in vim, by which we could examine the involvement of SR-A in apoptotic cell uptake [21] . Thymic M4 were isolated by a combination of enzymatic digestion with collagenase, followed by sedimentation through serum; thymic M 4 prepared in this way were recovered clustered with immature thymocytes. Staining with DNA dyes and the blood coagulant protein annexin V, which clearly fluorescent, indicating ingestion of apoptotic thymocytes. There was no evidence of uptake when they were incubated with labelled non-apoptotic cells, indicating that PKH2 labelling did not promote ingestion. Preincubation with the anti-SR-A mAb reduced uptake to about one-half of that of the control. Blocking with less specific ligands that can bind to more than one class of SR, such as polyguanylic acid, were more effective ( > 85% inhibition), whereas structurally related molecules that are not SR ligands, such as polycytidilic acid, were ineffective. As already stated, SR-A expression is not restricted to thymic M$. We therefore tested elicited peritoneal M 4 for SR-A-mediated phagocytic uptake. These peritoneal cells express SR-A and are capable of endocytosing modified lipoprotein via the receptor [18] . Tested under the conditions that were employed for investigating thymic M4, elicited peritoneal cells were also able to phagocytose apoptotic thymocytes ( Figure  Za) . A broader range of molecules that are known to be SR ligands were tested for their ability to inhibit uptake. All of the molecules that have been identified previously as SR ligands through their inhibition of the endocytosis of modified lipoprotein were able to reduce phagocytosis significantly (again > 90% reduction), whereas all the non-SR ligands had no effect. Interestingly, as was seen for thymic M4, uptake in the presence of 2F8 mAb was approximately one-half that of the control. No inhibition was observed with a mAb against type 3 complement receptor (CR3), which is also a phagocytic receptor, or an antibody against the vitronectin receptor which is known to mediate uptake of apoptotic neutrophils by blood-derived M 4 [23] .
The observation that inhibition with the mAb specific for SR-A was lower than that with less specific SR inhibitors, implied that either the mAb was not an efficient inhibitor of the SR-A component or that SR other than SR-A contribute to the phagocytosis of apoptotic thymocytes. We were able to address this problem by testing the phagocytic activity of M 4 prepared from SR-A-deficient mice. These animals were generated through homologous recombination to delete the SR-A gene [24] . Peritoneal M 4 from these mice have a significantly reduced ability to endocytose modified lipoprotein and delayed adherence and spreading in culture. Mice that lack SR-A develop smaller atherosclerotic lesions when crossed with apolipoprotein E knockout mice and are more susceptible to Listeriu infection, confirming roles for the receptor in vascular disease and host defence. They are also hypersensitive to endotoxin-mediated shock [17] . Although a deficiency in modified lipoprotein was detected in vitro, no difference in clearance was detected when lipoprotein was injected into the SR-A knockout mice [25] . This clearance could be delayed by prior injection with a general SR inhibitor, suggesting the involvement of SR(s) other than SR-A. Thymic M 4 that were prepared from SR-A null mice (absence of the receptor was confirmed by staining with the specific mAb) were tested for the phagocytosis of apoptotic thymocytes: these cells had a 50%
reduction in phagocytic ability relative to cells from the background strain (Figure 2b ). This degree of inhibition was comparable with that of the mAb, confirming that SR-A is responsible for one-half of the phagocytic activity required for apoptotic thymocyte ingestion. Importantly, cells from the knockout mice did not display any apparent compensatory activity, such as the upregulation of other phagocytic mechanisms, that would have resulted in full activity. The residual non-SR-A component could be further diminished by pretreatment with less specific SR ligands such as polyguanylic acid, implying that other SR may mediate at least part of the remaining phagocytic activity. Experiments are currently in progress to identify these other SR. Elicited peritoneal M 4 that lack SR-A also have a reduced capacity for the phagocytosis of dying thymocytes that is typically in the range of 30-40% of controls (N. Platt, unpublished work). Terpstra et al. [26] have shown subsequently that resident peritoneal M 4 from the knockout mice have reduced binding and uptake of apoptotic thymocytes but not oxidized erythrocytes.
The availability of the receptor-deficient mice has enabled us to begin to evaluate SR-A involvement in apoptotic cell clearance in vivo. These mice are healthy and fertile, demonstratVolume 26 ing that they are not sufficiently impaired to compromise either development or health. Thymic architecture in these mice is apparently normal, as is the distribution of immature thymocyte populations. Thymic M$ are also apparently normal with respect to the frequency and expression of other M$-restricted antigens such as F4/80, Fa-11 and CR3 (N. Platt, unpublished work). A potential thymic phenotype in these mice that could be attributed to a deficiency in the phagocytosis of apoptotic thymocytes might be characterized by the presence of apoptotic, non-phagocytosed thymocytes ('free apoptotic cells'). Determination of the frequency of such cells was investigated by terminal deoxynucleotidyltransferase-mediated UTP end-labelling (TUNEL) [27] staining of tissue sections of thymus from knockout and wild-type mice and by fluorescence-activated cell sorting (FACS) analysis of apoptotic thymocyte frequency in single cell suspension. T o date, we have failed to reveal a consistent difference between the two mice strains using either technique. Although it is possible that SR-A plays no role in thymocyte clearance in vivo, this seems unlikely in view of the clear defect seen in vitro and would demand a complex argument involving receptor downregulation. Several other possibilities are more likely. Firstly, the data in vitm show that other receptor(s) are involved and these may be able to fully compensate in viva There is growing evidence that phagocytes express multiple and perhaps redundant phagocytic systems for apoptotic cell recognition [6, 7] . Secondly, the phagocytosis of dying cells is rapid and occurs early in the apoptotic programme and it is not known for how long apoptotic thymocytes remain intact (and therefore detectable) before fragmenting. The methods used may not have been suitable for detecting a transient population of cells. Finally, it is possible that SR-A mediates uptake of only a subpopulation of thymocytes. However, this study highlights the difficulty in demonstrating the role of a single receptor in a process that involves multiple activities. It is very likely that the precise contribution of SR-A and the consequences of ingestion by this molecule will only be established when we are able to manipulate the other phagocyte components. These studies are currently being undertaken. N.P. is supported by the M.R.C.
Introduction
Understanding the molecular mechanisms underlying phagocytic clearance of apoptotic cells is an important aim of current cell-death research. Intuitively it is expected that, in the absence of rapid, efficient, and non-phlogistic removal of apoptotic cells and bodies, the process of apoptosis would lose its physiological benefits and, through spillage of intracellular macromolecules, the dying cells would wreak havoc in a manner analogous to necrosis, causing damage to neighbouring cells, eliciting inflammation and perhaps also causing autoimmune disease (for reviews, see [l-31). In the simplest terms, the minimal requirements for clearance of apoptotic cells without losing the value of apoptosis are: (i) changes at the surface of apoptotic cells that occur before loss of plasma membrane integrity; (ii) recognition of one or more of these changes by one or more phagocyte receptors; and (iii) a subsequent phagocytic response that results in the engulfment of the apoptotic cell without release of pro-inflammatory mediators.
We have been studying the clearance of apoptotic leucocytes by the human professional phagocyte, the monocyte-derived macrophage, and have identified: (i) the intercellular adhesion molecule, intercellular adhesion molecule (1CAM)-3, as an important marker of apoptotic leucocytes that interacts with macrophages; (ii) the glycosyl-phosphatidylinositol (GP1)-linked glycoprotein CD14 as a macrophage receptor of apoptotic leucocytes; and (iii) a dichotomy in CD14-dependent macrophage responses, a noninflammatory response being elicited during clearance of apoptotic leucocytes and a proinflammatory response being activated during clearance of the CD14-binding endotoxin, lipopolysaccharide (LPS) (Figure 1 ).
CAM-3: a marker of apoptotic leucocytes that is recognized by macrophages

Certain anti-ICAM-3-specific monoclonal antibodies inhibit clearance of apoptotic leucocytes
We have screened a large number of monoclonal antibodies (mAbs), raised against a number of leucocyte cell-surface antigens, to determine their ability to inhibit recognition and phagocytosis of apoptotic leucocytes by monocytederived macrophages in vitro. This approach has defined two ICAM-3-specific mAbs, 3A9 and BU68, which are able to inhibit significantly recognition and phagocytosis of apoptotic leuco- Abbreviations used: ICAM, intercellular adhesion molecule; GPI, glycosyl-phosphatidylinositol; LPS, lipopolysaccharide; mAb, monoclonal antibody; LFA, leukocyte function-associated antigen; PS, phosphatidylserine; TNF, tumour necrosis factor. ' To whom correspondence should be addressed. 
